home / stock / rgnx / rgnx news

RGNX News and Press, REGENXBIO Inc. From 11/02/23

Stock Information
Company Name: REGENXBIO Inc.
Stock Symbol: RGNX
Market: NASDAQ
Website: regenxbio.com
Menu
RGNX RGNX Quote RGNX Short RGNX News RGNX Articles RGNX Message Board
Get RGNX Alerts

News, Short Squeeze, Breakout and More Instantly...
RGNX - Regenxbio: Biotech To Watch With 2 Possible Accelerated Approval Pathways

2023-11-02 17:33:57 ET Summary Regenxbio Inc. is making progress in its pipeline, aiming to have five gene therapies in late-stage testing or approved by 2025. The company's lead candidate, ABBV-RGX-314, is being developed for the treatment of wet age-related macular degeneration;...
RGNX - Stifel starts Regenxbio at buy; cites broad platform, deep portfolio

2023-11-01 13:58:13 ET More on Regenxbio Regenxbio: Promising Yet Risky Therapeutic Horizon Regenxbio: RGX-314 Continues Advancing With Solid Financials Regenxbio up after hours on early-stage Duchenne candidate Seeking Alpha’s Quant Rating on Regenxbi...

RGNX - REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights

REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights PR Newswire ROCKVILLE, Md. , Nov. 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conferenc...

RGNX - RGNX, AVDL and FRSH are among after hour movers

2023-10-31 17:24:37 ET Gainers: Freshworks (FRSH) +5% . Verve Therapeutics ( VERV ) +3% . Expensify ( EXFY ) +3% . REGENXBIO ( RGNX ) +3% . ACI Worldwide ( ACIW ) +3% . Losers: Big 5 Sporting Goods ( BGFV ) -11% . ...
RGNX - REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting PR Newswire ROCKVILLE, Md. , Oct. 30, 2023 /PRNewswire/ --  REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Academy of Ophthalmology (A...

RGNX - Regenxbio: Promising Yet Risky Therapeutic Horizon

2023-10-25 06:05:51 ET Summary Regenxbio's financial health is strong, with a robust current ratio and a significant cash runway, but revenues have declined and stock performance lags behind broader indices. RGX-121 offers potential in treating MPS II, uniquely addressing both sys...

RGNX - REGENXBIO to Participate in the Jefferies CNS/Neuro Summit

REGENXBIO to Participate in the Jefferies CNS/Neuro Summit PR Newswire ROCKVILLE, Md. , Oct. 5, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Jefferies CNS/Neuro Summit on Thursday, October 12, 2023 . ...
RGNX - Regenxbio up after hours on early-stage Duchenne candidate

2023-10-03 18:30:58 ET More on Regenxbio Regenxbio: RGX-314 Continues Advancing With Solid Financials REGENXBIO Inc. (RGNX) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Regenxbio Historical earnings data for Regenxbio Financ...

RGNX - OMEE, TNDM and RGNX are among after hour movers

2023-10-03 17:29:36 ET Gainers: Edgewise Therapeutics ( NASDAQ: EWTX ) +7% . Cantaloupe ( CTLP ) +6% . Computer Programs and Systems ( CPSI ) +6% . REGENXBIO  ( RGNX ) +5% . Tandem Diabetes Care ( TNDM ) +5% . Lose...

RGNX - REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE(TM) Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society

REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society PR Newswire RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an opti...
Previous 10 Next 10